These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1272 related articles for article (PubMed ID: 26183055)

  • 1. Recurrent invasive pneumococcal disease in children--host factors and vaccination response.
    Ingels HA
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.
    Ingels H; Rasmussen J; Andersen PH; Harboe ZB; Glismann S; Konradsen H; Hoffmann S; Valentiner-Branth P; Lambertsen L;
    Vaccine; 2012 Jun; 30(26):3944-50. PubMed ID: 22504662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunodeficiency among children with recurrent invasive pneumococcal disease.
    Ingels H; Schejbel L; Lundstedt AC; Jensen L; Laursen IA; Ryder LP; Heegaard NH; Konradsen H; Christensen JJ; Heilmann C; Marquart HV
    Pediatr Infect Dis J; 2015 Jun; 34(6):644-51. PubMed ID: 25831419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serologic response to pneumococcal vaccination in children experiencing recurrent invasive pneumococcal disease.
    Ingels HAS; Kantsø B; Slotved HC
    BMC Infect Dis; 2018 Aug; 18(1):366. PubMed ID: 30081840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent invasive pneumococcal disease in children: epidemiological, microbiological, and clinical aspects from a Danish 33-year nationwide survey (1980-2013).
    Ingels H; Lambertsen L; Harboe ZB; Marquart HV; Konradsen H; Christensen JJ; Heilmann C
    Scand J Infect Dis; 2014 Apr; 46(4):265-71. PubMed ID: 24628485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.
    van der Linden M; Weiß S; Falkenhorst G; Siedler A; Imöhl M; von Kries R
    Vaccine; 2012 Aug; 30(40):5880-5. PubMed ID: 22771186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme.
    Harboe ZB; Valentiner-Branth P; Benfield TL; Christensen JJ; Andersen PH; Howitz M; Krogfelt KA; Lambertsen L; Konradsen HB
    Vaccine; 2010 Mar; 28(14):2642-7. PubMed ID: 20096392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.
    Harboe ZB; Valentiner-Branth P; Ingels H; Rasmussen JN; Andersen PH; Bjerre CC; Goldblatt D; Ashton L; Haston M; Konradsen HB; Lambertsen L;
    PLoS One; 2013; 8(1):e51460. PubMed ID: 23365635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.
    García Gabarrot G; López Vega M; Pérez Giffoni G; Hernández S; Cardinal P; Félix V; Gabastou JM; Camou T;
    PLoS One; 2014; 9(11):e112337. PubMed ID: 25375647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
    Harboe ZB; Dalby T; Weinberger DM; Benfield T; Mølbak K; Slotved HC; Suppli CH; Konradsen HB; Valentiner-Branth P
    Clin Infect Dis; 2014 Oct; 59(8):1066-73. PubMed ID: 25034421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine.
    Hsu K; Pelton S; Karumuri S; Heisey-Grove D; Klein J;
    Pediatr Infect Dis J; 2005 Jan; 24(1):17-23. PubMed ID: 15665705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive pneumococcal disease in Danish children, 1996-2007, prior to the introduction of heptavalent pneumococcal conjugate vaccine.
    Winther TN; Kristensen TD; Kaltoft MS; Konradsen HB; Knudsen JD; Høgh B
    Acta Paediatr; 2009 Feb; 98(2):328-31. PubMed ID: 18983440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive pneumococcal disease: Clinical outcomes and patient characteristics 2-6 years after introduction of 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the Netherlands.
    Wagenvoort GH; Sanders EA; Vlaminckx BJ; Elberse KE; de Melker HE; van der Ende A; Knol MJ
    Vaccine; 2016 Feb; 34(8):1077-85. PubMed ID: 26778420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.